<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2449">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129280</url>
  </required_header>
  <id_info>
    <org_study_id>BE43244</org_study_id>
    <secondary_id>2021-000624-35</secondary_id>
    <nct_id>NCT05129280</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors</brief_title>
  <official_title>An Open-label, Multicenter, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy dose-escalation&#xD;
      and dose expansion study of RO7444973.The aim of this study is to evaluate the safety,&#xD;
      pharmacokinetics, pharmacodynamics, and preliminary efficacy of RO7444973 in participants&#xD;
      with unresectable and/or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive, solid&#xD;
      tumors, carrying the HLA-A*02:01 allele.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From start of treatment up to 90 days after last RO7444973 dose (up to 15 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>From start of treatment up to 21-28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From baseline up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From baseline up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 40 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From baseline to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 40 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From baseline to death from any cause (up to 40 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Serum Concentration of RO7444973 Over Time</measure>
    <time_frame>From baseline to end of treatment (EoT) visit within 28 days after the last dose (up to 13 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Percentage of Participants Positive for Anti-drug Antibodies (ADA) to RO7444973</measure>
    <time_frame>From baseline to end of treatment (EoT) visit within 28 days after the last dose (up to 13 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part I: Single Participant Cohort (SPC) Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part I, RO7444973 is administered intravenously (IV) every 3 weeks (Q3W) at a fixed dose in a single participant per dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: Multiple Participant Cohort (MPC) Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part II, RO7444973 is administered IV Q3W at a fixed dose in multiple participants per dose level. Step-up dosing may also be explored.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III: Recommended Phase 2 Dose (RP2D) Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on emerging data from Part II, an RP2D and dosing regimen will be further investigated in Part III.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7444973</intervention_name>
    <description>RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.</description>
    <arm_group_label>Part I: Single Participant Cohort (SPC) Dose Escalation</arm_group_label>
    <arm_group_label>Part II: Multiple Participant Cohort (MPC) Dose Escalation</arm_group_label>
    <arm_group_label>Part III: Recommended Phase 2 Dose (RP2D) Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants &gt;/= 30 kg or at 12 mg/kg for participants &lt; 30 kg.</description>
    <arm_group_label>Part I: Single Participant Cohort (SPC) Dose Escalation</arm_group_label>
    <arm_group_label>Part II: Multiple Participant Cohort (MPC) Dose Escalation</arm_group_label>
    <arm_group_label>Part III: Recommended Phase 2 Dose (RP2D) Expansion</arm_group_label>
    <other_name>Actemra, RoActemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Unresectable and/or metastatic solid tumors that have received standard-of-care (SOC)&#xD;
             therapies previously and have no other SOC options available&#xD;
&#xD;
          -  Confirmed HLA-A*02:01 haplotype&#xD;
&#xD;
          -  Confirmed MAGE-A4 expression&#xD;
&#xD;
          -  Radiologically measurable disease according to Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1&#xD;
&#xD;
          -  Life expectancy of &gt;/=12 weeks&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Absence of rapid disease progression, threat to vital organs or non-irradiated lesions&#xD;
             &gt;2 cm in diameter at critical sites&#xD;
&#xD;
          -  No significant ongoing toxicity from prior anticancer treatment&#xD;
&#xD;
          -  Adequate hematological function&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  If applicable, willingness to use contraceptive measures.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History or clinical evidence of CNS primary tumors or metastases&#xD;
&#xD;
          -  Another invasive malignancy in the last 2 years&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic or&#xD;
             other infection&#xD;
&#xD;
          -  Current or past history of CNS disease&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit informed consent&#xD;
&#xD;
          -  Active auto-immune disease or flare within 6 months prior to start of study treatment&#xD;
&#xD;
          -  Expected need for regular immunosuppressive therapy or with systemic corticosteroids&#xD;
&#xD;
          -  Insufficient washout from prior anti-cancer therapy&#xD;
&#xD;
          -  Prior treatment with a bispecific T-cell engaging or adoptive cell therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BE43244 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale Cancer Center; Medical Oncology</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Inst. ; Dept. of Medical Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Onkologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre NHS Trust - Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute of Cancer Research and Royal Marsden NHS</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust. Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

